trending Market Intelligence /marketintelligence/en/news-insights/trending/-9J5JjEbsMi8WpOaf1Ztow2 content esgSubNav
In This List

Taiwan Leader Biotech H1 loss widens 41.3% YOY


According to Market Intelligence, February 2023


Private Markets 360° | Episode 2: ESG maturity in private markets (with Josh Green of Novata)

Case Study

A Government Agency Gains a Clearer Perspective on Foreign Investment Activity


Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Taiwan Leader Biotech H1 loss widens 41.3% YOY

Taiwan Leader Biotech Corp. said its first-half normalized net income came to a loss of 70 Taiwan cents per share, compared with a loss of 56 cents per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of NT$24.7 million, compared with a loss of NT$17.5 million in the prior-year period.

Total revenue rose year over year to NT$10.1 million from NT$9.7 million, and total operating expenses rose 30.1% on an annual basis to NT$49.0 million from NT$37.7 million.

Reported net income totaled a loss of NT$39.5 million, or a loss of NT$1.11 per share, compared to a loss of NT$28.0 million, or a loss of 90 cents per share, in the prior-year period.

As of Aug. 15, US$1 was equivalent to NT$31.33.